Dutch Lipid Clinic Network low-density lipoprotein cholesterol criteria are associated with long-term mortality in the general population  by Séguro, Florent et al.
Archives of Cardiovascular Disease (2015) 108, 511—518
Available  online  at
ScienceDirect
www.sciencedirect.com
CLINICAL RESEARCH
Dutch  Lipid  Clinic  Network  low-density
lipoprotein  cholesterol  criteria  are
associated  with  long-term  mortality  in  the
general  population
Les  niveaux  de  cholestérol  des  lipoprotéines  de  basse  densité  du  Dutch  Lipid
Clinic  Network  sont  associés  à  la  mortalité  à  long  terme  en  population
générale
Florent  Séguroa,  Vanina  Bongardb,c,  Emilie  Bérardb,c,
Dorota  Taraszkiewicza,  Jean-Bernard  Ruidavetsb,c,
Jean  Ferrièresa,b,∗
a Fédération  de  cardiologie,  TSA  50032,  CHU  de  Rangueil,  31059  Toulouse  cedex  9,  France
b Département  d’épidémiologie,  économie  de  la  santé  et  santé  publique,  UMR1027  Inserm,
université Toulouse  III,  31073  Toulouse,  France
c Service  d’épidémiologie,  CHU  de  Toulouse,  31073  Toulouse,  France
Received  5  February  2015;  received  in  revised  form  16  April  2015;  accepted  17  April  2015
KEYWORDS
Heterozygous  familial
Summary
Background.  —  Heterozygous  familial  hypercholesterolaemia  (HeFH)  is  a  severe  autosomalhypercholestero-
laemia;
Cohort  study;
Mortality;
LDL-cholesterol
dominant disease  that  is  underdiagnosed,  inadequately  treated  and  has  a  severe  long-term  car-
diovascular  risk.  Few  studies  have  evaluated  the  long-term  risk  of  high  low-density  lipoprotein
cholesterol  (LDL-C)  concentrations.
Aim.  —  To  evaluate  long-term  mortality  in  a  large  cohort  of  healthy  subjects,  according  to  LDL-C
concentrations.
Abbreviations: CHD, Coronary heart disease; CI, Conﬁdence interval; DLCN, Dutch Lipid Clinic Network; HDL-C, High-density lipopro-
tein cholesterol; HeFH, Heterozygous familial hypercholesterolaemia; HR, Hazard ratio; LDL, Low-density lipoprotein; LDL-C, Low-density
lipoprotein cholesterol.
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Methods.  —  Based  on  a  sample  of  6956  subjects  visiting  a  preventive  cardiology  department,
we selected  adult  subjects  without  a  personal  history  of  cardiovascular  disease.  From  1995  to
2011, 4930  healthy  subjects  were  examined  and  followed  up  until  31  December  2011.  All-cause
deaths were  collected  exhaustively.  A  Cox-based  multivariable  analysis  evaluated  long-term
total mortality  risk  according  to  Dutch  Lipid  Clinic  Network  (DLCN)  LDL-C  concentrations.
Results. —  After  a  mean  follow-up  of  8.6  years,  123  all-cause  deaths  were  recorded  (cumula-
tive mortality  rate,  2.5%).  In  the  ﬁnal  multivariable  model,  major  risk  factors  such  as  age,
sex, tobacco  use  and  diabetes  were  signiﬁcantly  associated  with  mortality.  After  adjustment
for age,  sex,  tobacco  use,  hypertension,  diabetes  and  statin  therapy,  and  in  comparison  with
subjects with  LDL-C  <  4  mmol/L  (<  155  mg/dL),  subjects  with  LDL-C  between  4  and  <  5  mmol/L
(155 to  <  190  mg/dL)  had  a  hazard  ratio  (HR)  of  1.99  (95%  conﬁdence  interval  [CI]  1.31—3.02;
P =  0.001),  subjects  with  LDL-C  between  5  and  <  6.5  mmol/L  (190  to  <  250  mg/dL)  had  an  HR
of 1.81  (95%  CI,  1.06—3.02;  P  =  0.030),  subjects  with  LDL-C  between  6.5  and  <  8.5  mmol/L
(250 to  <  330  mg/dL)  had  an  HR  of  2.69  (95%  CI,  1.06—6.88;  P  =  0.038)  and  subjects  with  LDL-
C ≥  8.5  mmol/L  (≥  330  mg/dL)  had  an  HR  of  6.27  (95%  CI,  0.84—46.57;  P  =  0.073).  After  excluding
patients  on  statins  at  baseline,  subjects  with  LDL-C  ≥  8.5  mmol/L  (≥  330  mg/dL)  had  an  HR  of
8.17 (95%  CI,  1.08—62.73;  P  =  0.042).
Conclusions.  —  The  severity  of  LDL-C  elevation  is  associated  with  a  higher  risk  of  death  in  healthy
subjects. DLCN  LDL-C  concentrations  may  be  used  in  daily  practice  to  identify  patients  with
HeFH who  warrant  aggressive  treatment.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  L’hypercholestérolémie  familiale  hétérozygote  (HeFH)  est  une  maladie  auto-
somique  dominante  sévère.  L’HeFH  est  une  maladie  qui  est  sous-diagnostiquée  et
insufﬁsamment  traitée.  Le  risque  cardiovasculaire  à  long  terme  de  l’HeFH  est  sévère.  Peu
d’études ont  évalué  le  risque  à  long  terme  des  valeurs  élevées  de  LDL-cholestérol  (LDL-C).
Objectif.  —  Le  but  de  ce  travail  a  été  d’évaluer  la  mortalité  à  long  terme  d’une  large  cohorte
de sujets  sains  en  fonction  des  niveaux  de  LDL-C.
Méthodes.  — À  partir  d’un  échantillon  de  6956  patients  examinés  dans  un  service  de  cardiologie
préventive,  nous  avons  isolé  les  sujets  majeurs  sans  antécédents  personnels  de  maladie  cardio-
vasculaire.  De  1995  à  2011,  4930  sujets  sains  ont  été  examinés  et  suivis  jusqu’au  31  décembre
2011. L’ensemble  des  décès  toutes  causes  a  été  collecté.  Une  analyse  multivariée  par  méthode
de Cox  a  permis  d’évaluer  le  risque  de  mortalité  totale  à  long  terme  en  fonction  des  niveaux
de LDL-C  du  Dutch  Lipid  Clinic  Network  (DLCN).
Résultats.  —  Après  un  suivi  moyen  de  8,6  ans,  123  décès  toutes  causes  ont  été  enregistrés  (mor-
talité cumulative  de  2,5  %).  Dans  le  modèle  multivarié  ﬁnal,  les  facteurs  de  risque  majeurs  tels
que l’âge,  le  sexe,  le  tabagisme  et  le  diabète  sont  associés  signiﬁcativement  à  la  mortalité.
Après ajustement  pour  l’âge,  le  sexe,  le  tabac,  l’hypertension  artérielle,  le  diabète  et  un  traite-
ment par  statines  et  en  comparaison  avec  les  sujets  dont  le  LDL-C  est  <  4  mmol/L  (<  155  mg/dL),
les sujets  présentant  un  LDL-C  entre  4  et  <  5  mmol/L  (155  à  <  190  mg/dL)  ont  un  hazard  ratio  (HR)
de 1,99  (intervalle  de  conﬁance  [IC]  à  95  %,  1,31—3,02  ;  p  =  0,001],  les  sujets  présentant  un  LDL-C
entre 5  et  <  6,5  mmol/L  (190  à  <  250  mg/dL)  ont  un  HR  de  1,81  (IC  à  95  %,  1,06—3,02  ;  p  =  0,030),
les sujets  présentant  un  LDL-C  entre  6,5  et  <  8,5  mmol/L  (250  à  <  330  mg/dL)  ont  un  HR  de  2,69
(IC à  95  %,  1,06—6,88  ;  p  =  0,038)  et  les  sujets  dont  le  LDL-C  est  ≥  8,5  mmol/L  (≥  330  mg/dL)  ont
un HR  à  6,27  (IC  à  95  %,  0,84—46,57  ;  p  =  0,073).  Après  exclusion  des  patients  sous  statines  à
l’entrée,  les  sujets  dont  le  LDL-C  est  ≥  8,5  mmol/L  (≥  330  mg/dL)  ont  un  HR  à  8,17  (IC  à  95  %,
1,08—62,73  ;  p  =  0,042).
Conclusions.  —  La  sévérité  de  l’élévation  du  LDL-C  est  liée  à  une  augmentation  de  la  mor-
talité totale  chez  les  sujets  sains.  Les  niveaux  de  LDL-C  de  la  DLCN  peuvent  être  utilisés  en
pratique quotidienne  pour  sélectionner  les  patients  porteurs  d’une  HeFH  et  ainsi  engager  une
thérapeutique  agressive.
© 2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
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chloride  precipitation  of  apolipoprotein  B-containing  lipo-
proteins.  LDL-C  was  determined  by  the  Friedewald
formula  when  triglycerides  were  <  4.6  mmol/L  (<  400  mg/dL)LDL-cholesterol  and  long-term  mortality  
Background
Heterozygous  familial  hypercholesterolaemia  (HeFH)  is  an
autosomal  dominant  disorder  with  a  severe  cardiovascu-
lar  prognosis.  A  deﬁnite  diagnosis  of  HeFH  requires  genetic
testing  for  mutations  primarily  located  on  the  low-density
lipoprotein  (LDL)  receptor,  apolipoprotein  B  and  proprotein
convertase  subtilisin/kexin  type  9  (PCSK9).  Patients  with
HeFH  are  perceived  as  being  at  high  risk,  according  to  the
European  Society  of  Cardiology  [1].  The  European  Society  of
Atherosclerosis  recommends  extensive  screening  for  HeFH
in  the  general  population  [2].  Screening  of  a  given  sub-
ject  allows  the  whole  family  to  be  assessed  and  leads  to
management  of  all  those  exposed  to  hypercholesterolaemia
[3].
HeFH  is  a  severe  disease  because  of  its  well-documented
cardiovascular  and  survival  prognosis  [4,5].  As  a  deﬁnite
diagnosis  is  based  on  testing  for  mutations  [6],  this  genetic
diagnostic  test  is  appropriate  for  the  majority  of  subjects
with  elevated  LDL-cholesterol  (LDL-C)  concentrations.  Nev-
ertheless,  most  developed  countries  are  not  equipped  with
sufﬁcient  genetic  centres  to  conduct  extensive  diagnostic
tests  in  subjects  for  whom  this  diagnosis  has  been  sug-
gested.  Hence,  scientiﬁc  societies  mostly  propose  the  use
of  scores,  such  as  the  USA  MEDPED  (Make  Early  Diagnosis  to
Prevent  Early  Death)  score,  the  UK  Simon  Broome  score  and
the  Dutch  Lipid  Clinic  Network  (DLCN)  score  [2].  With  the
exception  of  the  USA  score,  the  other  scores  are  based  on
a  collection  of  clinical  and  laboratory  data,  which  are  not
necessarily  found  in  the  medical  records.
The  DLCN  score  [2]  is  based  on  a  combination  of  ﬁve
dimensions.  The  ﬁrst  group  corresponds  to  a  ﬁrst-degree
relative  with  known  premature  (<  55  years,  men;  <  60  years,
women)  coronary  heart  disease  (CHD)  (1  point),  or  a  ﬁrst-
degree  relative  with  known  LDL-C  >  95th  percentile  by  age
and  sex  for  country  (1  point),  or  a  ﬁrst-degree  relative
with  tendon  xanthoma  and/or  corneal  arcus  (2  points),  or  a
child/children  aged  <  18  years  with  LDL-C  >  95th  percentile
by  age  and  sex  for  country  (2  points).  The  second  group  cor-
responds  to  premature  (<  55  years,  men;  <  60  years,  women)
CHD  (2  points)  or  premature  (<  55  years,  men;  <  60  years,
women)  cerebral  or  peripheral  vascular  disease  (1  point).
The  third  group  corresponds  to  the  presence  of  tendon  xan-
thoma  (6  points)  or  corneal  arcus  in  a  person  aged  <  45
years  (4  points).  The  fourth  group  corresponds  to  LDL-C  con-
centrations:  ≥  8.5  mmol/L  (≥  330  mg/dL)  (8  points);  ≥  6.5
to  <  8.5  mmol/L  (≥  250  to  <  330  mg/dL)  (5  points);  ≥  5.0
to  <  6.5  mmol/L  (≥  190  to  <  250  mg/dL)  (3  points);  ≥  4.0  to
<  5.0  mmol/L  (≥  155  to  <  190  mg/dL)  (1  point).  The  ﬁfth
group  corresponds  to  deoxyribonucleic  acid  (DNA)  analy-
sis  and  the  ﬁnding  of  a  causative  mutation  (8  points).  A
‘‘deﬁnite  HeFH’’  diagnosis  can  be  made  if  the  subject
scores  >  8  points.  A  ‘‘probable  HeFH’’  diagnosis  can  be  made
if  the  subject  scores  6  to  8  points.  A  ‘‘possible  HeFH’’  diag-
nosis  can  be  made  if  the  subject  scores  3  to  5  points.  An
‘‘unlikely  HeFH’’  diagnosis  can  be  made  if  the  subject  scores
0  to  2  points.  However,  this  long  list  of  variables  is  not  usually
found  in  current  clinical  charts.  So,  we  sought  to  propose  a
simpler  tool  for  screening  for  HeFH  in  general  practice.
The  aim  of  this  research  was  to  determine  whether  DLCN
LDL-C  concentrations  affect  the  survival  prognosis  in  healthy
subjects,  and  may  thus  be  used  in  the  general  population. [513
ethods
tudy population
e  conducted  a  prospective  cohort  study,  which  included
956  apparently  healthy  asymptomatic  subjects.  Partici-
ants  were  included  between  November  1995  and  December
011  at  the  Department  of  Preventive  Cardiology  in  our
eaching  institution  (Toulouse  University  Hospital,  Toulouse,
rance).  These  subjects  were  either  self-referred  or
eferred  by  their  primary-care  physician  or  their  cardiol-
gist  for  cardiovascular  risk  assessment,  management  of
ardiovascular  risk  factors  or  routine  ambulatory  screening
or  cardiovascular  diseases  (CVDs)  [7—10].  Patients  with  a
ersonal  history  of  coronary  heart  disease  (International
lassiﬁcation  of  Disease,  9th  revision,  codes  410.0  to  414.9),
 personal  history  of  stroke  (codes  433.0  to  438.9  except
37.3  to  437.7),  a personal  history  of  atherosclerosis  (codes
40.0  to  440.9)  or  a  personal  history  of  aneurysms  (codes
41.0  to  442.9)  were  excluded.  Vital  status  on  31  December
011  was  obtained  for  each  participant  through  the  national
atabase  that  records  all  deaths  occurring  in  the  French  pop-
lation  each  year  (RNIPP)  [11].  Authorisation  to  use  these
ata  was  obtained  in  accordance  with  French  law  (Commis-
ion  nationale  de  l’informatique  et  des  libertés  [CNIL]).
uestionnaires and measurement of clinical
ariables
t  baseline,  extensive  questionnaires  were  ﬁlled  in  by
rained  medical  staff  during  a  personal  interview  with  the
articipant.  Information  on  exposures  was  collected  at  base-
ine  only.  Data  concerning  socioeconomic  level,  personal
edical  history,  cardiovascular  risk  factors,  lifestyle  habits
nd  drug  intake  were  recorded.  Participants  were  asked  to
ring  their  latest  drug  prescription  to  the  inclusion  visit.
ll  drugs  taken  during  the  2  weeks  preceding  the  visit  were
ecorded.  Family  history  of  premature  CVD  (before  55  years
n  father/65  years  in  mother)  was  recorded.  People  who
urrently  smoked  or  who  had  stopped  for  <  3  years  were
onsidered  as  current  smokers.  Height,  weight  and  arte-
ial  blood  pressure  (mean  of  two  measurements  performed
ith  a  standard  sphygmomanometer  in  a  seated  position
fter  ≥  5  minutes  rest)  were  measured  according  to  stan-
ardised  protocols  by  the  medical  staff.  Body  mass  index
as  calculated  as  weight  divided  by  height  squared  (kg/m2).
ypertension  was  assessed  for  people  with  blood  pres-
ure  ≥  140/90  mmHg  or  on  treatment.  Diabetes  was  assessed
or  subjects  receiving  hypoglycaemic  drugs  or  with  fasting
lood  glucose  ≥  7  mmol/L.
aboratory methods
lood  samples  were  taken  after  ≥  10  hours  of  overnight
asting.  Serum  total  cholesterol  and  triglycerides  were
easured  by  enzymatic  assays  (Boehringer,  Mannheim,
ermany).  High-density  lipoprotein  cholesterol  (HDL-C)
as  measured  after  sodium  phosphotungstate-magnesium12]. Glucose  concentrations  were  measured  using  a
5 F.  Séguro  et  al.
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Table  1  Subjects  taking  part  in  the  cohort  study.
Number  of
patients
Total  examined  up  to  31  December
2011
6956
Examined  for  the  ﬁrst  time  5182
Minors  (<  18  years)  10
History  of  ischaemic  heart  disease  131
History  of  stroke 66
History  of  documented
atherosclerosis
34
History  of  vascular  aneurysm  3
Undocumented  blood  pressure  4
Lipid  proﬁle  not  performed  4
Followed  up  4930
Cumulative  number  of  deaths 123
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onventional  enzymatic  method  based  on  hexokinase-
lucose-6-phosphate  dehydrogenase.
tatistical analysis
tatistical  analysis  was  performed  using  STATA  statistical
oftware,  release  11.2  (STATA  Corporation,  College  Station,
X,  USA).  Subjects  with  a  history  of  CVD  were  excluded  from
he  analysis.
We  ﬁrst  described  the  baseline  characteristics  of  partic-
pants  and  compared  baseline  characteristics  by  outcome
ccurrence,  comparing  subjects  who  did  not  die  (i.e.  those
live  on  31  December  2011)  with  subjects  who  had  a  fatal
vent  during  follow-up.  Qualitative  variables  were  com-
ared  between  groups  using  the  2 test  (or  Fisher’s  exact
est  when  necessary).  Student’s  t-test  was  used  to  compare
he  distribution  of  quantitative  data  (or  the  Mann—Whitney
est  when  distribution  departed  from  normality  or  when
omoscedasticity  was  rejected).
Survival  was  then  analysed.  Events  were  cases  of  death,
nd  exposure  was  deﬁned  by  LDL-C  concentration  at  inclu-
ion.  Hazard  ratios  (HRs)  for  mortality  and  95%  conﬁdence
ntervals  (CIs)  were  assessed  using  a  Cox  model.  The
ndependent  variables  initially  introduced  into  the  sur-
ival  model  were  LDL-C  concentrations  at  inclusion  and  all
ariables  associated  with  mortality  in  the  univariate  anal-
sis  (P-value  <  0.20).  A  backward  analysis  was  then  applied
ntil  only  variables  signiﬁcantly  and  independently  associ-
ted  with  mortality  (P-value  <  0.05)  remained.  Hypertension
as  included  in  the  ﬁnal  model  because  it  is  a  classical
isk  factor.  The  proportional-hazard  assumption  was  tested
or  each  covariate  by  the  ‘‘log-log’’  plot  method  curves
—ln{—ln[survival]}),  for  each  category  of  nominal  covari-
te,  versus  (ln[analysis  time]).  None  of  the  assumptions
ould  be  rejected.
esults
 total  of  6956  subjects  visited  the  Department  of  Preven-
ive  Cardiology  from  November  1995  to  December  2011.
fter  excluding  minors  and  patients  with  CVD  at  inclu-
ion,  together  with  patients  who  returned  to  the  same
epartment  on  several  occasions,  we  reached  a  total  of
930  subjects  who  could  be  followed  up  until  31  December
011  (Table  1).
After  a  mean  follow-up  period  of  8.6  years,  123  deaths
ere  recorded  (cumulative  mortality  rate  of  2.5%).  Among
he  4930  healthy  subjects  at  baseline,  LDL-C  could  not  be
alculated  in  106  patients  (including  two  deaths)  because  of
xcessively  high  triglyceride  concentrations.
The  clinical  and  laboratory  characteristics  of  the  study
opulation  are  shown  in  Table  2.  The  mean  age  of  subjects
as  52  years,  59.4%  were  men,  25.3%  were  regular  smok-
rs  and  5.2%  were  diabetic.  At  inclusion,  26.8%  of  patients
ere  receiving  statin  therapy  and  the  mean  LDL-C  value  was
 mmol/L  (155  mg/dL)  in  the  overall  sample.
When  the  sample  was  stratiﬁed  according  to  DLCN  LDL-Concentrations,  54.6%  had  LDL-C  <  4  mmol/L  (<  155  mg/dL),
8.3%  had  LDL-C  between  4  and  <  5  mmol/L  (155  to
 190  mg/dL),  14.2%  had  LDL-C  between  5  and  <  6.5  mmol/L
190  to  <  250  mg/dL),  2.5%  had  LDL-C  between  6.5  and
I
f
a
ramong  those  followed  up
 8.5  mmol/L  (250  to  <  330  mg/dL)  and  0.4%  had  LDL-
 ≥  8.5  mmol/L  (≥  330  mg/dL).
All  of  the  conventional  risk  factors  were  more  severe
mong  those  who  died  during  follow-up;  this  was  particularly
rue  for  LDL-C  concentration.  Table  3  presents  the  multi-
ariable  analysis,  adjusted  for  age  and  sex,  which  shows
he  inﬂuence  of  the  main  risk  factors  on  survival  prognosis,
ogether  with  the  risk  level  related  to  LDL-C  concentrations.
In  the  multivariable  analysis,  LDL-C  concentrations  were
tatistically  associated  with  overall  mortality  (Table  4).
fter  adjustment  for  age,  sex,  tobacco  use,  hypertension,
iabetes  and  statin  therapy,  and  in  comparison  with  subjects
ith  LDL-C  <  4  mmol/L  (155  mg/dL),  subjects  with  LDL-C
etween  4 and  <  5  mmol/L  (155  to  <  190  mg/dL)  had  an  HR
f  1.99  (95%  CI,  1.31—3.02;  P  =  0.001),  subjects  with  LDL-C
etween  5  and  <  6.5  mmol/L  (190  to  <  250  mg/dL)  had  an  HR
f  1.81  (95%  CI,  1.06—3.02;  P  =  0.030),  subjects  with  LDL-C
etween  6.5  and  <  8.5  mmol/L  (250  to  <  330  mg/dL)  had  an
R  of  2.69  (95%  CI,  1.06—6.88;  P  =  0.038)  and  subjects  with
DL-C  ≥  8.5  mmol/L  (330  mg/dL)  had  an  HR  of  6.27  (95%  CI,
.84—46.57;  P  =  0.073).  After  excluding  patients  on  statins  at
aseline,  subjects  with  LDL-C  ≥  8.5  mmol/L  (≥  330  mg/dL)
ad  an  HR  of  8.17  (95%  CI,  1.08—62.73;  P  =  0.042)  (Table  5).
fter  excluding  patients  treated  with  statins  at  inclusion,  all
LCN  LDL-C  concentrations  (with  the  exception  of  the  LDL-C
lass  between  5  and  <  6.5  mmol/L  [190  to  <  250  mg/dL])  were
tatistically  associated  with  an  impaired  survival  prognosis.
hen  these  thresholds  were  modiﬁed  (Appendix  A),  LDL-C
etween  4  and  <  6.5  mmol/L  (155  to  <  250  mg/dL)  was  asso-
iated  with  an  HR  of  2.07  (95%  CI,  1.33—3.23;  P  =  0.001)  and
DL-C  ≥  6.5  mmol/L  (≥  250  mg/dL)  was  associated  with  an
R  of  3.82  (95%  CI,  1.46—10.07;  P  =  0.006)  in  healthy  subjects
ot  treated  with  a  statin  at  inclusion.
iscussion
n  a  large  sample  of  healthy  subjects  undergoing  long-term
ollow-up,  LDL-C  >  4  mmol/L  (155  mg/dL)  was  signiﬁcantly
ssociated  with  higher  overall  mortality.  When  LDL-C
eached  high  values,  such  as  6.5  mmol/L  (250  mg/dL)  or
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Table  2  Clinical  and  laboratory  characteristics.
All  Alive  Deceased  P
(n  =  4930) (n  =  4807) (n  =  123)
Age  (years)  52  ±  10  52  ±  10  55  ±  11  <  0.01
Men  2927  (59.4) 2821  (58.7) 106  (86.2)  <  0.01
Current  smoker 1248  (25.3) 1198  (24.9) 50  (40.7) <  0.01
Body  mass  index  (kg/m2) 26  ±  9 26  ±  9 25  ±  5 0.3
Diabetes  255  (5.2)  237  (4.9)  18  (14.6)  <  0.01
Family  history  of  premature  CVD  723  (14.7)  708  (14.7)  15  (12.2)  0.62
Systolic  blood  pressure  (mmHg)  136  ±  18  136  ±  17  146  ±  20  <  0.01
Diastolic  blood  pressure  (mmHg)  83  ±  9  82  ±  9  86  ±  10  <  0.01
Pulse  pressure  (mmHg)  54  ±  13  53  ±  13  60  ±  16  <  0.01
Estimated  GFR  (mL/min/1.73  m2)  80  ±  17  80  ±  17  79  ±  18  0.5
Antihypertensive  drug  treatment  981  (19.9)  952  (19.8)  29  (23.6)  0.3
Statins  1323  (26.8)  1298  (27.0)  25  (20.3)  0.09
Total  cholesterol  (mmol/L)  6.17  ±  1.30  6.16  ±  1.30  6.46  ±  1.45  0.01
LDL-C  (mmol/L)a 4.00  ±  1.19  3.99  ±  1.19  4.37  ±  1.21  <  0.01
HDL-C  (mmol/L) 1.41  ±  0.42  1.41  ±  0.42  1.30  ±  0.38  <  0.01
Triglycerides  (mmol/L)  1.75  ±  1.72  1.75  ±  1.73  1.79  ±  1.21  0.79
LDL-C  <  4  mmol/L  (<  155  mg/dL)a 2632  (54.6)  2587  (55.0)  45  (37.2)  <  0.01
4  ≤  LDL-C  <  5  mmol/L  (155  to  <  190  mg/dL)a 1367  (28.3) 1318  (28.0)  49  (40.5)  <  0.01
5  ≤  LDL-C  <  6.5  mmol/L  (190  to  <  250  mg/dL)a 684  (14.2)  663  (14.1)  21  (17.4)  0.31
6.5  ≤  LDL-C  <  8.5  mmol/L  (250  to  <  330  mg/dL)a 123  (2.5) 118  (2.5)  5  (4.1)  0.26
LDL-C  ≥  8.5  mmol/L  (≥  330  mg/dL)a 18  (0.4) 17  (0.4) 1  (0.8)  0.41
Data are expressed as mean ± standard deviation or number (%). CVD: cardiovascular disease; GFR: glomerular ﬁltration rate; HDL-C:
high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol.
a LDL-C could not be calculated in 106 of 4930 patients (including two deaths) because of excessively high triglyceride concentrations.
Table  3 Survival,  as  per  the  multivariable  analysis  (adjusted  for  age  and  sex).
HR  95%  CI  P
Current  smoking  2.2  [1.50—3.22]  <  0.01
Body  mass  index  (kg/m2)  1.01  [0.99—1.02]  0.39
Diabetes  2.62  [1.57—4.36]  <  0.01
Family  history  of  premature  CVD  0.85  [0.49—1.46]  0.56
Systolic  blood  pressure  (mmHg)  1.01  [1.01—1.02]  0.02
Diastolic  blood  pressure  (mmHg)  1.01  [0.99—1.03]  0.48
Pulse  pressure  (mmHg)  1.02  [1.01—1.03]  0.01
Estimated  GFR  (mL/min/1.73  m2)  1  [0.99—1.01]  0.86
Hypertension  1.21  [0.83—1.78]  0.32
Statins  0.7  [0.45—1.09]  0.11
Total  cholesterol  (mmol/L)  1.21  [1.06—1.38]  <  0.01
LDL-C  (mmol/L)  1.25  [1.09—1.44]  <  0.01
HDL-C  (mmol/L)  0.97  [0.59—1.61]  0.91
Triglycerides  (mmol/L)  0.99  [0.87—1.12]  0.84
LDL-C  <  4  mmol/L  (<  155  mg/dL)  1
4  ≤  LDL-C  <  5  mmol/L  (155  to  <  190  mg/dL)  1.84  [1.23—2.77]  <  0.01
5  ≤  LDL-C  <  6.5  mmol/L  (190  to  <  250  mg/dL)  1.64  [0.97—2.76]  0.06
6.5  ≤  LDL-C  <  8.5  mmol/L  (250  to  <  330  mg/dL)  2.47  [0.97—6.28]  0.06
LDL-C  ≥  8.5  mmol/L  (≥  330  mg/dL) 5.57  [0.75—41.07]  0.09
CI: conﬁdence interval; CVD: cardiovascular disease; GFR: glomerular ﬁltration rate; HDL-C: high-density lipoprotein cholesterol; HR:
hazard ratio; LDL-C: low-density lipoprotein cholesterol.
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Table  4  Association  between  overall  mortality  and  Dutch  Lipid  Clinic  Network  low-density  lipoprotein  cholesterol  con-
centrations,  as  per  the  multivariable  analysis  (adjustment  for  age,  sex,  tobacco  use,  hypertension,  diabetes  and  statin
therapy).
HR  (95%  CI)  P
LDL-C  <  4  mmol/L  (<  155  mg/dL) 1
4  ≤  LDL-C  <  5  mmol/L  (155  to  <  190  mg/dL) 1.99 (1.31—3.02) 0.001
5  ≤  LDL-C  <  6  .5  mmol/L  (190  to  <  250  mg/dL)  1.81  (1.06—3.02)  0.03
6.5  ≤  LDL-C  <  8.5  mmol/L  (250  to  <  330  mg/dL)  2.69  (1.06—6.88)  0.038
LDL-C  ≥  8.5  mmol/L  (≥  330  mg/dL)  6.27  (0.84—46.57)  0.073
CI: conﬁdence interval; HR: hazard ratio; LDL-C: low-density lipoprotein cholesterol.
Table  5 Association  between  overall  mortality  and  Dutch  Lipid  Clinic  Network  low-density  lipoprotein  cholesterol  con-
centrations,  as  per  the  multivariable  analysis  (adjustment  for  age,  sex,  tobacco  use,  hypertension  and  diabetes),  with
exclusion  of  all  patients  on  statins.
HR  (95%  CI)  P
LDL-C  <  4  mmol/L  (<  155  mg/dL) 1
4  ≤  LDL-C  <  5  mmol/L  (155  to  <  190  mg/dL) 2.19 (1.37—3.50) 0.001
5  ≤  LDL-C  <  6.5  mmol/L  (190  to  <  250  mg/dL) 1.81 (0.98—3.35) 0.059
6.5  ≤  LDL-C  <  8.5  mmol/L  (250  to  <  330  mg/dL) 3.38 (1.17—9.97) 0.024
LDL-C  ≥  8.5  mmol/L  (≥  330  mg/dL) 8.17 (1.08—62.73) 0.042
CI: conﬁdence interval; HR: hazard ratio; LDL-C: low-density lipoprotein cholesterol.
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t.5  mmol/L  (330  mg/dL),  the  risk  was  very  high,  with  a rela-
ive  risk  of  3  or  8  for  overall  mortality.  These  high  LDL-C
alues  strongly  suggest  a  diagnosis  of  HeFH  and  warrant
ggressive  management.
HeFH  is  a  severe  disease,  which  is  straightforward  to
iagnose  if  the  patient  presents  tendon  xanthomas,  corneal
rcus,  family  history  of  early-onset  CVD  or  high  cholesterol  in
he  family  [2,3].  The  presence  of  other  risk  factors  increases
he  cardiovascular  risk  in  HeFH  [5].  A  deﬁnite  diagnosis  of
eFH  is  obtained  when  a  genetic  diagnostic  test  is  used;
 network  of  centres  offering  this  genetic  testing  exists  in
rance  [6].
HeFH  is  a  common  autosomal  dominant  disease,  the
revalence  of  which  is  estimated  at  1  in  500  subjects.  Nev-
rtheless,  because  of  time  constraints  general  practitioners
r  cardiologists  rarely  diagnose  it.  However,  this  diagnosis
an  be  readily  suggested  when  faced  with  elevated  LDL-C
oncentrations  associated  with  a  higher  cardiovascular  risk
4].
In  the  general  population,  initiation  of  statin  therapy  for
rimary  prevention  is  associated  with  an  improvement  in
ardiovascular  mortality  and  overall  mortality  [13,14]. Sim-
larly,  in  the  general  population,  LDL-C  is  associated  with
igher  overall  mortality.  In  NHANES  III  [15],  LDL-C  concen-
rations  ≥  3.35  mmol/L  (≥  130  mg/dL)  were  associated  with relative  risk  of  overall  mortality  of  2.0  (95%  CI,  1.70—2.33)
fter  a  14-year  follow-up.
Initiation  of  aggressive  treatment  for  HeFH  is  equally
ble  to  correct  the  cardiovascular  prognosis  and  improve  the
w
n
m
turvival  prognosis.  Hence,  in  two  recent  studies,  when  HeFH
as  treated  as  part  of  primary  prevention,  life  expectancy
as  identical  to  that  of  the  general  population  [16,17].
In  a  recent  study  [16]  based  on  the  follow-up  of
688  patients  with  HeFH  conﬁrmed  by  a  genetic  diagno-
is,  the  authors  recorded  113  deaths  over  a mean  follow-up
eriod  of  8  years  (cumulative  mortality  rate  of  2.4%).
ur  sample  in  the  general  population  presents  the  same
verall  mortality  as  this  sample  of  subjects  with  genetically-
iagnosed  HeFH.  This  appears  to  favour  the  inclusion,  in  our
ample,  of  patients  genuinely  presenting  HeFH,  who  had
ot  been  clinically  or  genetically  diagnosed.  Furthermore,
n  the  MEDPED  study  conducted  in  1993  [18],  LDL-C  values
f  6.5  mmol/L  (250  mg/dL)  in  the  general  population  were
ssociated  with  a 68.4%  probability  of  having  HeFH,  LDL-C
alues  of  6.8  mmol/L  (264  mg/dL)  were  associated  with  an
8.2%  probability  of  having  HeFH,  while  LDL-C  values  in  the
egion  of  8.5  mmol/L  (330  mg/dL)  were  linked  with  a  100%
robability  of  having  HeFH.  Hence,  the  values  observed  in
ur  sample  suggest  a  high  probability  of  undiagnosed  HeFH.
Our  study  has  a  number  of  limitations.  Cardiovascular
ortality  was  not  recorded  because  it  is  known  to  be  con-
iderably  underestimated  based  on  death  certiﬁcates  in
rance.  We  recorded  family  history  of  CVD  in  a  conven-
ional  manner;  however,  we  are  not  convinced  that  this
as  a  fully  comprehensive  approach,  as  most  patients  can-
ot  remember  the  date  of  onset  of  the  disease  in  family
embers.  Furthermore,  observations  did  not  include  repor-
ing  of  tendon  xanthomas  or  corneal  arcus.  Lastly,  routine
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genetic  diagnostic  tests  have  only  become  available  at  the
centre  very  recently,  so  we  were  unable  to  make  use  of
genetic  diagnostic  results  obtained  in  recent  years.  How-
ever,  according  to  the  literature,  in  10%  to  40%  of  all  cases,
no  causative  mutations  are  found,  despite  a  typical  clinical
presentation  [2].
Our  sample  population  can  be  assumed  to  be  at  greater
risk  than  the  general  population.  In  a  recent  study  (Bérard
E.,  personal  communication),  we  showed  that  the  life
expectancy  of  our  sample  was  similar  to  that  of  the  gen-
eral  population  in  the  same  region.  Consequently,  DLCN
LDL-C  concentrations  may  be  used  in  the  general  popula-
tion  to  screen  for  potential  HeFH  patients.  In  these  patients
with  high  LDL-C  concentrations,  extending  the  patient  inter-
view  to  include  speciﬁc  investigation  of  a  family  history  of
hypercholesterolaemia  or  early-onset  CVD  and  the  clinical
examination  to  include  investigation  of  corneal  arcus  and
tendon  xanthomas  may  be  proposed.
Conclusions
DLCN  LDL-C  concentrations  are  associated  with  overall
mortality  in  France.  Total  mortality  increases  as  LDL-C
concentrations  increase.  These  ﬁndings  should  prompt  the
French  medical  community  to  screen  for  HeFH  as  exten-
sively  as  possible,  and  to  adopt  an  aggressive  management
approach  for  those  patients  with  the  highest  LDL-C  concen-
trations.  Lastly,  elevated  LDL-C  concentrations  in  a  given
patient  should  prompt  us  to  screen  all  family  members  for
HeFH.
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Appendix ATable  1  Association  between  overall  mortality  and  Dutch
Lipid  Clinic  Network  low-density  lipoprotein  cholesterol  con-
centrations,  as  per  the  multivariable  analysis  (adjustment
for  age,  sex,  tobacco  use,  hypertension,  diabetes  and  statin
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HR  (95%  CI)  P
LDL-C  <  4  mmol/L
(< 155  mg/dL)
1
4  ≤  LDL-C  <  6.5  mmol/L
(155  to  <  250  mg/dL)
1.93 (1.31—2.85)  0.001
LDL-C  ≥  6.5  mmol/L
(≥  250  mg/dL)
2.98  (1.25—7.08)  0.014
I: conﬁdence interval; HR: hazard ratio; LDL-C: low-density
ipoprotein cholesterol.
Table  2  Association  between  overall  mortality  and  Dutch
ipid  Clinic  Network  low-density  lipoprotein  cholesterol  con-
entrations,  as  per  the  multivariable  analysis  (adjustment
or  age,  sex,  tobacco  use,  hypertension  and  diabetes),  with
xclusion  of  all  patients  on  statins.
HR  (95%  CI)  P
DL-C  <  4  mmol/L
(< 155  mg/dL)
1
 ≤  LDL-C  <  6.5  mmol/L
(155  to  <  250  mg/dL)
2.07 (1.33—3.23)  0.001
DL-C  ≥  6.5  mmol/L
(≥  250  mg/dL)
3.82  (1.46—10.07)  0.006
I: conﬁdence interval; HR: hazard ratio; LDL-C: low-density
ipoprotein cholesterol.
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